Back to School: How biopharma can reboot drug development. Access exclusive analysis here

0813 ECP Aerovate
BioCentury & Getty Images

Emerging Company Profile

RA-incubated Aerovate to deploy $72.6M series A for inhaled imatinib for PAH

Powder aerosol formulations designed to avoid systemic effects that tripped up Novartis’ oral version

Aerovate’s powder aerosol formulations for rare pulmonary diseases are designed to avoid systemic effects.

Aug 13, 2020 | 10:54 PM GMT

Aerovate emerged from RA Capital’s incubator last

Read the full 586 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE